Unknown.jpg
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
February 19, 2024 18:25 ET | Opthea Limited
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Unknown.jpg
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
February 14, 2024 07:00 ET | Opthea Limited
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 ...
Unknown.jpg
Opthea Strengthens Team with Key Clinical and Regulatory Hires
February 01, 2024 06:00 ET | Opthea Limited
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology...
optima-logo.png
Opthea to Receive US$35M Commitment and Additional US$50M Funding
December 27, 2023 06:00 ET | Opthea Limited
Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended...
optima-logo.png
Opthea Receives A$8.8 million R&D Tax Incentive
December 19, 2023 06:00 ET | Opthea Limited
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea to Present at the FLORetina 2023 Congress
December 01, 2023 05:30 ET | Opthea Limited
MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea to Present at the Jefferies 2023 London Healthcare Conference
November 09, 2023 05:30 ET | Opthea Limited
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
October 30, 2023 05:30 ET | Opthea Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 27, 2023 05:30 ET | Opthea Limited
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter...
optima-logo.png
Opthea to Participate at the 2023 Euretina Congress
October 02, 2023 05:30 ET | Opthea Limited
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...